| Model Number |
305U225 |
| Medical Device Problem Codes |
Calcified (1077); Device Stenosis (4066)
|
| Health Effect - Clinical Codes |
Aortic Valve Stenosis (1717); Calcium Deposits/Calcification (1758)
|
| Date of Event |
11/20/2025
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
It was reported that 9 years and 5 months post implant of this 25 mm aortic bioprosthetic valve, the patient is being evaluated for a transcatheter valve-in-valve replacement.The reason for evaluation was not reported.It was stated that calcium was seen in the left ventricular outflow tract (lvot) under the left coronary cusp (lcc), the right coronary cusp (rcc), non-coronary cusp (ncc) and sino-tubular junction (stj).It was also reported that anterior calcification was seen in the right femoral artery (rfa).No intervention or adverse patient effects were reported.
|
| |
|
Event or Problem Description
|
|
Additional information was received that reported subsequently, 13 days later, a transcatheter valve was implanted valve-in-valve.The reason for intervention was not reported.No additional adverse patient effects were reported.
|
| |
|
Additional Manufacturer Narrative
|
|
Updated data: b.1: adv evnt/prod prob.B.2: outcome attributed to adverse event.B.3: date of event: b.5: event description.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Additional Manufacturer Narrative
|
|
B5 and h6 updated.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
| |
|
Event or Problem Description
|
|
Additional information was received that reason for intervention was stenosis.No additional adverse patient effects were reported.
|
| |
|
Search Alerts/Recalls
|